C-reactive protein and metabolic syndrome in women with previous gestational diabetes. 2007

G Di Cianni, and C Lencioni, and L Volpe, and A Ghio, and I Cuccuru, and G Pellegrini, and L Benzi, and R Miccoli, and S Del Prato
Department of Endocrinology and Metabolism, Section of Diabetes and Metabolic Diseases, University of Pisa and Azienda Ospedaliera Pisana, Pisa, Italy. dicianni@immr.med.unipi.it

BACKGROUND This study evaluates the presence of metabolic syndrome (MS) and its association with C-reactive protein (CRP) and other cardiovascular (CV) risk factors, in a sample of women with and without previous Gestational Diabetes (pGDM). METHODS One hundred and sixty-six women with pGDM and 98 women (controls) with uncomplicated pregnancy were studied 16 months after delivery. In all women, plasma glucose, insulin, lipid profile, serum uric acid, C-reactive protein, fibrinogen and homocysteine were measured. MS was defined according to NCEP ATPIII criteria. RESULTS MS was identified in 15 pGDM women (9%) versus 1 control (1%) (p < 0.001). The more frequent metabolic traits were abdominal obesity (36% vs 17%) and low HDL-cholesterol (34% vs 17% in pGDM women and controls, respectively; all p < 0.01). HOMA-R, LDL-cholesterol, fibrinogen, serum uric acid and CRP resulted significantly higher in pGDM women with MS as compared to those without MS after adjustment for BMI. In women with no criteria for MS, only CRP levels were found to be higher in pGDM women compared to controls (p < 0.05). Seventeen percent of pGDM women with no criteria for MS had CRP levels >or=1 mg/L (all controls showed CRP levels <1 mg/L). After a stepwise regression analysis, CRP levels were independently correlated to HOMA-R (r2 = 0.27, p < 0.001) and fibrinogen (r2 = 0.30, p < 0.001). CONCLUSIONS In our population, MS occurs in a sizable proportion of pGDM women and is associated with increased levels of CRP, fibrinogen, uric acid and LDL-cholesterol. Moreover, higher levels of CRP, a marker of chronic low-grade inflammation, are present in a subset of women with pGDM, independently of MS.

UI MeSH Term Description Entries
D008075 Lipoproteins, HDL A class of lipoproteins of small size (4-13 nm) and dense (greater than 1.063 g/ml) particles. HDL lipoproteins, synthesized in the liver without a lipid core, accumulate cholesterol esters from peripheral tissues and transport them to the liver for re-utilization or elimination from the body (the reverse cholesterol transport). Their major protein component is APOLIPOPROTEIN A-I. HDL also shuttle APOLIPOPROTEINS C and APOLIPOPROTEINS E to and from triglyceride-rich lipoproteins during their catabolism. HDL plasma level has been inversely correlated with the risk of cardiovascular diseases. High Density Lipoprotein,High-Density Lipoprotein,High-Density Lipoproteins,alpha-Lipoprotein,alpha-Lipoproteins,Heavy Lipoproteins,alpha-1 Lipoprotein,Density Lipoprotein, High,HDL Lipoproteins,High Density Lipoproteins,Lipoprotein, High Density,Lipoprotein, High-Density,Lipoproteins, Heavy,Lipoproteins, High-Density,alpha Lipoprotein,alpha Lipoproteins
D009765 Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
D010298 Parity The number of offspring a female has borne. It is contrasted with GRAVIDITY, which refers to the number of pregnancies, regardless of outcome. Multiparity,Nulliparity,Primiparity,Parity Progression Ratio,Parity Progression Ratios,Ratio, Parity Progression,Ratios, Parity Progression
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D002097 C-Reactive Protein A plasma protein that circulates in increased amounts during inflammation and after tissue damage. C-Reactive Protein measured by more sensitive methods often for coronary heart disease risk assessment is referred to as High Sensitivity C-Reactive Protein (hs-CRP). High Sensitivity C-Reactive Protein,hs-CRP,hsCRP,C Reactive Protein,High Sensitivity C Reactive Protein
D005260 Female Females
D005340 Fibrinogen Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products. Coagulation Factor I,Factor I,Blood Coagulation Factor I,gamma-Fibrinogen,Factor I, Coagulation,gamma Fibrinogen
D006710 Homocysteine A thiol-containing amino acid formed by a demethylation of METHIONINE. 2-amino-4-mercaptobutyric acid,Homocysteine, L-Isomer,2 amino 4 mercaptobutyric acid,Homocysteine, L Isomer,L-Isomer Homocysteine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

G Di Cianni, and C Lencioni, and L Volpe, and A Ghio, and I Cuccuru, and G Pellegrini, and L Benzi, and R Miccoli, and S Del Prato
October 2007, Diabetes research and clinical practice,
G Di Cianni, and C Lencioni, and L Volpe, and A Ghio, and I Cuccuru, and G Pellegrini, and L Benzi, and R Miccoli, and S Del Prato
June 2021, Scientific reports,
G Di Cianni, and C Lencioni, and L Volpe, and A Ghio, and I Cuccuru, and G Pellegrini, and L Benzi, and R Miccoli, and S Del Prato
January 2011, Diabetes research and clinical practice,
G Di Cianni, and C Lencioni, and L Volpe, and A Ghio, and I Cuccuru, and G Pellegrini, and L Benzi, and R Miccoli, and S Del Prato
September 2012, Diabetes/metabolism research and reviews,
G Di Cianni, and C Lencioni, and L Volpe, and A Ghio, and I Cuccuru, and G Pellegrini, and L Benzi, and R Miccoli, and S Del Prato
January 2013, Journal of diabetes and metabolic disorders,
G Di Cianni, and C Lencioni, and L Volpe, and A Ghio, and I Cuccuru, and G Pellegrini, and L Benzi, and R Miccoli, and S Del Prato
August 2005, The Tohoku journal of experimental medicine,
G Di Cianni, and C Lencioni, and L Volpe, and A Ghio, and I Cuccuru, and G Pellegrini, and L Benzi, and R Miccoli, and S Del Prato
March 2015, Endocrine,
G Di Cianni, and C Lencioni, and L Volpe, and A Ghio, and I Cuccuru, and G Pellegrini, and L Benzi, and R Miccoli, and S Del Prato
November 2005, Chang Gung medical journal,
G Di Cianni, and C Lencioni, and L Volpe, and A Ghio, and I Cuccuru, and G Pellegrini, and L Benzi, and R Miccoli, and S Del Prato
April 2015, International journal of endocrinology and metabolism,
G Di Cianni, and C Lencioni, and L Volpe, and A Ghio, and I Cuccuru, and G Pellegrini, and L Benzi, and R Miccoli, and S Del Prato
August 2002, Diabetes care,
Copied contents to your clipboard!